Phase II study alternating mFOLFOX 6 and FOLFIRI (FIREFOX) plus bevacizumab (bev) regimen in first-line treatment of advanced colorectal cancer in Japanese patients (KSCC 0801).

被引：0
|
作者：
Ogata, Yutaka
Akagi, Yoshito
Kakeji, Yoshihiro
Emi, Yasunori
Oki, Eiji
Saeki, Hiroshi
Touyama, Tetsuo
Samura, Hironori
Baba, Hideo
Natsugoe, Shoji
Shirouzu, Kazuo
Tokunaga, Shoji
Maehara, Yoshihiko
机构：
[1] Kurume Univ, Dept Surg, Kurume Med Ctr, Sch Med, Kurume, Fukuoka, Japan
[2] Kurume Univ, Dept Surg, Sch Med, Kurume, Fukuoka, Japan
[3] Kyushu Univ, Dept Surg & Sci, Fukuoka, Japan
[4] Nakagami Hosp, Okinawa, Japan
[5] Univ Ryukyus, Dept Surg 1, Nishihara, Okinawa, Japan
[6] Kumamoto Univ, Dept Surg Gastroenterol, Kumamoto, Japan
[7] Kagashima Univ, Dept Gastrointestinal Surg, Kagoshima, Japan
[8] Kyushu Univ Hosp, Med Informat Ctr, Fukuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.602
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
602
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A prospective study of XELIRI plus bevacizumab as the first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101).
    Hanazono, Koichi
    Emi, Yasunori
    Tsuji, Akihito
    Kishihara, Fumiaki
    Oki, Eiji
    Hamanoue, Masahiro
    Baba, Hideo
    Natsugoe, Shoji
    Ogata, Yutaka
    Sakai, Kenji
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [32] Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial
    Oki, Eiji
    Makiyama, Akitaka
    Miyamoto, Yuji
    Kotaka, Masahiko
    Kawanaka, Hirofumi
    Miwa, Keisuke
    Kabashima, Akira
    Noguchi, Tomohiro
    Yuge, Kotaro
    Kashiwada, Tomomi
    Ando, Koji
    Shimokawa, Mototsugu
    Saeki, Hiroshi
    Akagi, Yoshito
    Baba, Hideo
    Maehara, Yoshihiko
    Mori, Masaki
    CANCER MEDICINE, 2021, 10 (02): : 454 - 461
  • [33] Phase II randomized study of Folfiri vs Folfiri plus Celecoxib in first line treatment of advanced colorectal cancer (ACRC)
    Maiello, E.
    Giuliani, F.
    Romito, S.
    Pezzella, G.
    Mallamaci, R.
    Di Renzo, G.
    Di Bisceglie, M.
    Gebbia, V.
    Lopez, M.
    Colucci, G.
    ANNALS OF ONCOLOGY, 2005, 16 : 148 - 148
  • [34] Efficacy and safety of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC).
    Zhou, Fuxiang
    Wang Wen-bo
    Xia, Ling
    Dai, Jing
    Wu, Han
    Yang, Lei
    Xiong, Zhiguo
    Gong, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 152 - 152
  • [35] Phase II randomized study of FOLFIRI vs FOLFIRI plus celecoxib in first line treatment of advanced colorectal cancer (ACRC).
    Maiello, E
    Giuliani, F
    Romito, S
    Pezzella, G
    Mallamaci, R
    Di Renzo, N
    Di Bisceglie, M
    Gebbia, V
    Lopez, M
    Colucci, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 284S - 284S
  • [36] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer
    Kopetz, S.
    Glover, K. Y.
    Eng, C.
    Wolff, R. A.
    Chang, D. Z.
    Adinin, R. B.
    Morris, J.
    Abbruzzese, J. L.
    Hoff, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer
    Kearney, Matthew R.
    Chen, Emerson Y.
    Vaccaro, Gina M.
    Strother, John
    Burt, Andrea
    Todd, Kendra
    Donovan, Jeff
    Kampa-Schittenhelm, Kerstin M.
    Lopez, Charles D.
    ANTICANCER RESEARCH, 2019, 39 (01) : 245 - 252
  • [38] Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
    Eiji Oki
    Yasunori Emi
    Takeharu Yamanaka
    Hiroyuki Uetake
    Kei Muro
    Takao Takahashi
    Takeshi Nagasaka
    Etsuro Hatano
    Hitoshi Ojima
    Dai Manaka
    Tetsuya Kusumoto
    Yu Katayose
    Toshiyoshi Fujiwara
    Kazuhiro Yoshida
    Michiaki Unno
    Ichinosuke Hyodo
    Naohiro Tomita
    Kenichi Sugihara
    Yoshihiko Maehara
    British Journal of Cancer, 2019, 121 : 222 - 229
  • [39] Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
    Oki, Eiji
    Emi, Yasunori
    Yamanaka, Takeharu
    Uetake, Hiroyuki
    Muro, Kei
    Takahashi, Takao
    Nagasaka, Takeshi
    Hatano, Etsuro
    Ojima, Hitoshi
    Manaka, Dai
    Kusumoto, Tetsuya
    Katayose, Yu
    Fujiwara, Toshiyoshi
    Yoshida, Kazuhiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Sugihara, Kenichi
    Maehara, Yoshihiko
    BRITISH JOURNAL OF CANCER, 2019, 121 (03) : 222 - 229
  • [40] Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer:: a phase II study
    Feliu, J
    Salud, A
    Escudero, P
    Lòpez-Gómez, L
    Pericay, C
    Castañón, C
    de Tejada, MRL
    Rodríguez-García, JM
    Martínez, MP
    Martín, MS
    Sánchez, JJ
    Barón, MG
    BRITISH JOURNAL OF CANCER, 2004, 90 (08) : 1502 - 1507
12345